# OnCo record nct05840211 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05840211/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05840211", "NCT05840211" ;
  schema:name "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy"@en ;
  schema:alternateName "ASCENT-07"@en ;
  schema:description "A phase 3 trial of Sacituzumab govitecan and Capecitabine in HR-positive / HER2-negative breast cancer, run by Gilead Sciences, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05840211/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05840211> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-05-08" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/gilead/> .